课题基金 / 基金详情

DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS

DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS
多剂量 Palifermin (RHUKGF) 治疗艾滋病的双盲 II 期研究
批准号：
7951580
负责人：
RONALD T. MITSUYASU
金额：
$4.99万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-04-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7951580
关键词：
Acquired Immunodeficiency SyndromeCD4 Lymphocyte CountClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDoseDouble-Blind MethodFundingGrantInstitutionPhase II Clinical TrialsPlacebosResearchResearch PersonnelResourcesSourceTimeTreatment ProtocolsUnited States National Institutes of Healthkeratinocyte growth factor

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 为了证明与安慰剂相比，在12周的时间点，使用三种剂量方案之一的帕利福明的绝对CD4淋巴细胞计数有更大的上升。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To demonstrate a greater rise in absolute CD4+ lymphocyte count with one of the three dose regimens of palifermin compared with placebo at the week 12 time point.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)